HD-PRO-TRIAD (TM) Validation: A Patient-reported Instrument for the Symptom Triad of Huntington's Disease

被引:13
|
作者
Carlozzi, Noelle E. [1 ]
Victorson, David [2 ]
Sung, Victor [3 ]
Beaumont, Jennifer L. [2 ]
Cheng, Wendy [4 ]
Gorin, Brian [4 ]
Duh, Mei Sheng [4 ]
Samuelson, David [4 ]
Tulsky, David [5 ,6 ]
Gutierrez, Sandra [2 ]
Nowinski, Cindy J. [2 ]
Mueller, Allison [2 ]
Shen, Vivienne [7 ]
Frank, Samuel [8 ]
机构
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Northwestern Univ, Evanston, IL USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Anal Grp Inc, Boston, MA USA
[5] NYU, Langone Med Ctr, New York, NY USA
[6] Kessler Fdn, W Orange, NJ USA
[7] Lundbeck LLC, Deerfield, IL USA
[8] Boston Univ, Sch Med, Boston, MA 02118 USA
关键词
Huntington's disease; quality-of-life scale; psychometric validation; patient-reported outcome; health-related quality of life; HD-PRO-TRIAD (TM);
D O I
10.7916/D8PN93NZ
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Few valid, disease-specific measures of health-related quality of life (HRQOL) capture the spectrum of symptoms associated with Huntington's disease (HD). The HD-PRO-TRIAD (TM) is a new, HD-specific, patient-reported outcome (PRO) instrument of the HD symptom triad (cognitive decline, emotional/behavioral dyscontrol, and motor dysfunction) designed for clinical research and practice. The objective was to validate the HD-PRO-TRIAD (TM) through a cross-sectional sample of individuals with HD and caregivers. Methods: Development of the HD-PRO-TRIAD (TM) has been described elsewhere. A total of 132 individuals with HD and 40 HD caregivers, comprising 29 dyads, participated in the cross-sectional psychometric validation of this instrument. Participants provided responses to the HD-PRO-TRIAD (TM) and other HRQOL and disease severity instruments (EuroQOL 5D, Short Form 12, Neuro-QOL Item Banks, PROMIS Global Health, and self-reported Unified Huntington's Disease Rating Scale Total Functional Capacity and Independence Scales). Internal consistency, construct validity, and patient-caregiver proxy consistency were evaluated. Results: Internal consistency of the three domains and overall HD-PRO-TRIAD (TM) instrument was supported by Cronbach's alpha values >= 0.94. Construct validity was supported by significant correlations between HD-PRO-TRIAD (TM) domain scores and other measures of the same domains (e.g., significant positive correlations between HD-PRO-TRIAD (TM) Anxiety with Neuro-QOL Anxiety), as well as slightly weaker but still strong correlations with other HRQOL instruments (e.g., HD-PRO-TRIAD (TM) Anxiety and UHDRS Independence; all p < 0.01). Consistency between patient self-report and caregiver proxy report was supported by an intra-class correlation coefficient >= 0.92 for all three domains and the overall instrument. Discussion: These data indicate that HD-PRO-TRIAD (TM) is a reliable and valid HRQOL instrument that captures the typical triad of HD symptoms.
引用
收藏
页数:21
相关论文
共 50 条
  • [1] Patient-reported impact of symptoms in Huntington disease: PRISM-HD
    Glidden, Alistair M.
    Luebbe, Elizabeth A.
    Elson, Molly J.
    Goldenthal, Steven B.
    Snyder, Christopher W.
    Zizzi, Christine E.
    Dorsey, E. Ray
    Heatwole, Chad R.
    [J]. NEUROLOGY, 2020, 94 (19) : E2045 - E2053
  • [2] Development and psychometric validation of the Nausea/vomiting symptom assessment patient-reported outcome (PRO) instrument for adults with secondary hyperparathyroidism
    McHorney C.A.
    Bensink M.E.
    Burke L.B.
    Belozeroff V.
    Gwaltney C.
    [J]. Journal of Patient-Reported Outcomes, 2 (1)
  • [3] Development of a Novel Patient-Reported Outcome Measure for Huntington's Disease: The Huntington Disease Health Index (HD-HI) Study
    Glidden, Alistair
    Luebbe, Elizabeth
    Elson, Molly
    Goldenthal, Steven
    Dorsey, E. Ray
    Heatwole, Chad
    [J]. NEUROTHERAPEUTICS, 2018, 15 (01) : 245 - 246
  • [4] Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument
    Matthew Reaney
    Veleka Allen
    Amy J. Sehnert
    Liang Fang
    Albert A. Hagège
    Srihari S. Naidu
    Iacopo Olivotto
    [J]. PharmacoEconomics - Open, 2022, 6 : 563 - 574
  • [5] Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument
    Reaney, Matthew
    Allen, Veleka
    Sehnert, Amy J.
    Fang, Liang
    Hagege, Albert A.
    Naidu, Srihari S.
    Olivotto, Iacopo
    [J]. PHARMACOECONOMICS-OPEN, 2022, 6 (04) : 563 - 574
  • [6] Development of a Novel Patient-Reported Outcome Measure for Huntington Disease: The Huntington Disease Health Index (HD-HI) Study
    Glidden, Alistair M.
    Luebbe, Elizabeth A.
    Elson, Molly J.
    Goldenthal, Steven B.
    Snyder, Christopher W.
    Zizzi, Christine E.
    Brumfield, Olivia S.
    Dorsey, Ray
    Heatwole, Chad R.
    [J]. NEUROTHERAPEUTICS, 2019, 16 (04) : 1361 - 1362
  • [7] Psychometric Evaluation of a New Patient-Reported Outcome (PRO) Symptom Diary for Varicose Veins: VVSymQA® Instrument
    Wright, David D. I.
    Paty, Jean
    Turner-Bowker, Diane M.
    Bradbury, Andrew
    [J]. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2016, 9 (04): : 335 - 348
  • [8] Psychometric Evaluation of a New Patient-Reported Outcome (PRO) Symptom Diary for Varicose Veins: VVSymQ® Instrument
    David D. I. Wright
    Jean Paty
    Diane M. Turner-Bowker
    Andrew Bradbury
    [J]. The Patient - Patient-Centered Outcomes Research, 2016, 9 : 335 - 348
  • [9] Development and Validation of a Primary Sclerosing Cholangitis Patient-Reported Outcome (PSC-PRO) Instrument
    Younossi, Zobair M.
    Afendy, Arian
    Stepanova, Maria
    Racila, Andrei
    Nader, Fatema
    Gomel, Rachel
    Safer, Ricky
    Myers, Robert P.
    Subramanian, Mani
    McHutchison, John G.
    Levy, Cynthia
    Bowlus, Christopher L.
    Kowdley, Kris V.
    Muir, Andrew J.
    [J]. HEPATOLOGY, 2017, 66 : 724A - 724A